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Abstract
Background—Maternal periodontal infection is associated with an increased risk for 
preeclampsia. Periodontal infection is also associatedwith increased oxidative stress. Our objective 
was to determine the relationship among maternal periodontal disease, maternal oxidative stress, 
and the development of preeclampsia.
Methods—A secondary analysis of prospectively collected data from the Oral Conditions and 
Pregnancy Study was performed. A cohort of healthy women enrolled at <26 weeks of gestation 
underwent an oral examination, serum sampling, and delivery follow-up. Aperiodontal infection 
was categorized by clinical parameters as healthy or mild or moderate/severe periodontal 
infection. Preeclampsia was defined by the American Congress of Obstetricians and 
Gynecologists criteria as blood pressure >140/90 mmHg and ≥1+ proteinuria on a catheterized 
specimen. Maternal blood was assayed for 8-isoprostane concentrations using an enzyme-linked 
immunosorbent assay and stratified as elevated (≥75th percentile) or not elevated (<75th 
percentile). Odds ratios (ORs) for preeclampsia were calculated and stratified by periodontal 
disease and the level of 8-isoprostane concentration.
Results—A total of 34 (4.3%) of 791 women developed preeclampsia. Women with an 8-
isoprostane concentration ≥75th percentile at enrollment were more likely to develop preeclampsia 
compared to women with an 8-isoprostane concentration <75th percentile (38.2% versus 24.4%, 
respectively; P = 0.07; OR: 1.91; 95% confidence interval [CI]: 0.94 to 3.90). Among women with 
moderate/severe periodontal disease, an elevated 8-isoprostane concentration (≥75th percentile) 
did not significantly increase the likelihood for preeclampsia (adjusted OR: 2.08; 95% CI: 0.65 to 
6.60).
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Conclusions—Women with oxidative stress early in pregnancy, as measured by an 8-
isoprostane concentration ≥75th percentile, were at an increased risk for developing preeclampsia. 
The presence of periodontal disease did not appear to modify this risk.
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Oxidative stress occurs through the generation of reactive oxygen species and free radicals 
in excess of the available antioxidant buffering capacity.1 When an excess production of 
reactive oxygen species is formed, oxidative stress ensues. 8-Isoprostane prostaglandin (8-
iso PGF2α), a member of the isoprostane family, has been advocated as the “gold standard” 
for measurement of in vivo “whole body” oxidative stress.2,3 8-iso PGF2α is predominately 
generated by the cyclooxygenase independent free-radical attack on arachidonic acid in cell 
membranes.
Proteins, lipids, and DNA are susceptible to oxidative stress, resulting in a wide variety of 
chronic diseases and acute pathologic processes. Oxidative stress plays an important role in 
the pathogenesis of periodontal disease and its complications.4,5 Periodontal disease is a 
common oral infection, with a prevalence ranging from 10% to 60%.6 Gingivitis and 
periodontitis are two periodontal conditions of noteworthy significance during pregnancy. 
Gingivitis is an infectious and inflammatory condition of the superficial gingival tissues, 
with prevalence estimates during pregnancy ranging from 30% to 100%.7 Periodontal 
disease is a more severe condition, affecting 5% to 20% of pregnant women, and results in 
destruction of tooth-supporting structures.8
Individuals with periodontal disease display high levels of local and systemic biomarkers of 
oxidative stress.9 Among pregnant women, oxidative stress is one of the pathologic 
processes associated with preeclampsia. Preeclampsia is characterized by the overproduction 
of lipid peroxides and impaired antioxidant defense in the blood and placentas of women 
with preeclampsia.10,11 Women destined to develop preeclampsia have increased systemic 
concentrations of 8-iso PGF2α early in pregnancy prior to the clinical manifestation of the 
disease.12
It was reported13 that women with moderate/severe periodontal disease at delivery or 
disease progression during pregnancy are at an increased risk for preeclampsia. Several 
other investigators14–17 reported this finding; however, the underlying mechanism of this 
association is unknown but may be mediated, in part, by maternal systemic inflammatory 
responses.
We hypothesized that chronic exposure to the oral pathogens of periodontal infection leads 
to maternal systemic oxidative stress and preeclampsia, and oxidative stress may be one 
possible explanatory variable in this relationship. In this study, we investigate the 
relationship among maternal periodontal disease, maternal systemic oxidative stress, and the 
risk for preeclampsia.
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We performed a secondary analysis of data from the Oral Conditions and Pregnancy 
(OCAP) study.18 The OCAP study was a prospective cohort study of maternal periodontal 
disease and obstetric outcomes performed at the Center for Oral and Systemic Disease, 
School of Dentistry, University of North Carolina in collaboration with Duke University 
Medical Center from December 1997 through July 2001. The study design, procedures for 
patient enrollment, inclusion and exclusion criteria, clinical measurements, data collection 
methods, medical record abstraction, and biologic sampling methods were previously 
described.18 The Duke University Medical Center and the University of North Carolina 
Institutional Review Boards granted approval to conduct the study, and written informed 
consent was obtained from all study participants. Over a 42-month period, eligible healthy 
women with a singleton pregnancy were enrolled at <26 weeks of gestation. Women were 
excluded from the study if they were <18 years of age without a legal guardian, at >26 
weeks of gestation, had a multifetal gestation, chronic hypertension, pregestational diabetes, 
cardiac valvular disease, history of fenfluramine-phentermine use (unless a normal 
echocardiogram was documented), a medical condition that required antibiotics for 
prophylaxis during dental treatment, human immunodeficiency virus, or delivery was 
planned at another medical center. Gestational age was calculated by the date of the last 
menstrual period and was confirmed by a first-or second-trimester ultrasound examination. 
Demographic information, health behavior, and medical history data were obtained by a 
patient interview and questionnaire at the first visit and were reviewed by a physician at the 
first prenatal visit. Race was determined by a self-report. Details on the course of the 
pregnancy, labor, delivery, and the newborn were abstracted from the medical record and 
entered into the OCAP study database.§
Oral health examinations and maternal blood were collected at enrollment and at delivery. 
The periodontal disease status of patients was defined as healthy, mild, or moderate/severe 
based on clinical criteria.19 A healthy periodontal disease status was defined as no sites with 
pockets ≥4 mm and no sites with bleeding pockets >3 mm. Mild periodontal disease was 
defined as <15 sites with the presence of one or more pockets ≥4 mm or one or more 
pockets with bleeding. Moderate/severe periodontal disease was considered present if ≥15 
sites demonstrated a probing depth ≥4 mm. Preeclampsia was categorized as two episodes of 
blood pressure >140/90 mmHg and ≥1+ proteinuria on a catheterized urine specimen.
The 8-isoprostane quantification was performed with a commercially available ultrasensitive 
enzyme-linked immunoassay|| at a single laboratory at the Center for Oral and Systemic 
Disease, School of Dentistry, University of North Carolina. The lower limit of detection of 
this assay was 0.022 pg/ml with an inter- and intraassay variability of 5.4% and 10.4%, 
respectively. For this analysis, plasma quartile concentrations of 8-isoprostane ≥75th 
percentile, which corresponds to a concentration >81,870 pg/ml, were defined as elevated. 
8-isoprostane concentrations were determined to be low at <75th percentile or elevated at 
≥75th percentile and were examined as a categoric variable.
§Microsoft Access, 1997 SR2, Microsoft, Redmond, WA.
||Assay Designs: Direct 8-iso-PGF2alpha kit, Biomol, Hamburg, Germany.
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A bivariate analysis was performed on a priori candidate confounders to determine the 
association between an elevated maternal plasma 8-isoprostane concentration and the 
development of preeclampsia using the χ2 or Student t test. Variables were considered 
confounders if they changed the association between periodontal disease and preeclampsia 
by ≥5%. All confounding variables were included in a multivariable logistic regression 
model. The smoking history of patients was also included in the model. Odds ratios (ORs) 
and 95% confidence intervals (CIs) for a risk of preeclampsia were determined by stratifying 
periodontal disease as healthy/mild, moderate/severe, or absent and 8-isoprostane 
concentrations ≥75th and <75th percentile. All analyses were performed using a statistical 
program.¶
RESULTS
A total of 1,020 women aged 19 to 38 years were enrolled in the OCAP study and 
considered for analysis. Of these women, 791 (78%) had an oral health examination and 8-
isoprostane results. No significant differences were found in age, race, parity, marital status, 
gestational age, tobacco use, insurance status, periodontal disease, and preeclampsia 
between women with and without plasma 8-isoprostane results (data not shown).
Maternal demographic characteristics and obstetric data are illustrated in Table 1. Thirty-
four women (4.3%) developed preeclampsia. Women with preeclampsia were similar to 
those without preeclampsia, except for mean gestational age at delivery. Oxidative stress 
and periodontal disease status are shown in Table 2. The mean ± SD and median (inter-
quartile range [IQR]) values of 8-isoprostane concentrations for women with preeclampsia 
tended to be higher than those without preeclampsia. Women with an 8-isoprostane 
concentration ≥75th percentile at enrollment were more likely to develop preeclampsia 
compared to women with an 8-isoprostane concentration <75th percentile, but this was not 
statistically significant (38.2% versus 24.4%, respectively; P = 0.07; OR: 1.91; 95% CI: 
0.94 to 3.90).
Adjusted ORs for preeclampsia among women with an 8-isoprostane concentration ≥75th 
percentile, a periodontal disease state, and the combination of both exposures are illustrated 
in Table 3. Among women with periodontal disease, the presence of 8-isoprostane ≥75th 
percentile did not significantly increase the odds for the development of preeclampsia.
DISCUSSION
Moderate/severe periodontal infection at delivery and periodontal disease progression were 
reported to be associated with an increased risk for preeclampsia.19 In addition, it was 
suggested that maternal systemic inflammation may play a role in this process.17 The results 
of the present analysis, after adjustment for potential confounders, do not suggest that the 
relationship between periodontal disease and preeclampsia, as measured by maternal plasma 
8-isoprostane concentrations early in pregnancy, may be mediated by maternal oxidative 
¶Statistical Analytical Systems 9.1, SAS Institute, Cary, NC.
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stress. This is the first report, to our knowledge, that hypothesizes that periodontal disease 
and preeclampsia may be linked through maternal systemic oxidative stress responses.
Pregnancy, per se, is a state of oxidative stress arising from the increased metabolic activity 
in placental mitochondria and the reduced scavenging power of antioxidants.20 Consistent 
with previous reports, 12,21,22 we found elevated plasma levels of 8 isoprostane in patients 
with preeclampsia. Isoprostanes are a specific marker of oxidative damage to lipids from 
endogenous lipid peroxidation. They are prostaglandin-like compounds derived by 
autooxidation of the arachidonic acid moiety.23
Chappell et al.12 conducted a longitudinal study of biochemical markers in women at risk 
for preeclampsia and found a trend toward elevated plasma concentrations of 8-isoprostane 
in preeclamptic women (increase: 51%; 95% CI: 0.99 to 2.31; P = 0.055). In a prospective 
observational study, Rogers et al.24 found that women who developed gestational 
hypertension/preeclampsia had significantly higher concentrations of 8-isoprostane between 
24 to 32 weeks than normotensive women (764.6 ± 517.1 versus 191.9 ± 173.7, 
respectively; P <0.001). Chappell et al.25 conducted a clinical trial of supplementation with 
vitamins C and E in gravid women at a high risk for preeclampsia. When Chappell et al.25 
compared baseline concentrations of isoprostane in high-risk women to those in low-risk 
control subjects before random assignment of antioxidant supplements or placebo, 
isoprostane concentrations at baseline in the high-risk group were 40% higher than those in 
the low-risk group. During the remainder of the gestation, isoprostane concentrations 
remained elevated in high-risk women on the placebo but fell to the levels of the low-risk 
women in those assigned to antioxidant supplements.
Several limitations of our study merit discussion. A few investigators failed to find an 
association between periodontal disease and preeclampsia.26,27 Some investigators28–30 
failed to find a relationship between elevated 8-isoprostane concentrations and preeclampsia. 
Plausible explanations for these different findings include population and demographic 
differences. Our study population included a significant number of African American 
women who are known to have worse periodontal disease than their white counterparts and 
have higher concentrations of systemic inflammation.31 Our study also reported a 4% rate of 
preeclampsia, which likely allowed for an improved assessment of the association between 
preeclampsia and inflammatory oral health conditions compared to other populations that 
reported a lower preeclampsia rate.30
Additionally, one inherent difficulty in our analysis was the relatively infrequent events of 
preeclampsia with and without moderate to severe periodontal diseases, thus yielding small 
numbers of events for statistical analysis even from this large cohort of women. It is possible 
that significant results could be obtained with a larger cohort by combining these results 
with future studies in a meta-analysis.
8-isoprostane is a highly sensitive marker for systemic oxidative stress. It is influenced by 
many factors other than periodontal infection, including smoking, dyslipidemia, diabetes, 
hyperhomocysteinemia, obesity, diet, and oral antioxidant consumption.32 The OCAP study 
does not provide specific details on dietary habits or the use of over-the-counter vitamin 
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supplementation, thus we were limited in the ability to account for these variables in our 
analysis. There is also limited longitudinal data to characterize 8-isoprostane concentrations 
during pregnancy. We chose to use the 75th percentile as a cutoff point to represent those 
women whom we felt were in the highest risk category.
CONCLUSIONS
In conclusion, women with oxidative stress early in pregnancy, as measured in this study by 
an 8-isoprostane concentration ≥75th percentile, had an increased risk for the development 
of preeclampsia. Periodontal disease does not appear to significantly modify this risk. Future 
research is needed to gather longitudinal data on biomarkers of oxidative stress and to 
determine whether the treatment of maternal periodontal disease decreases maternal 
oxidative stress during pregnancy.
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Table 1
Demographic and Obstetric Characteristics of the Study Population*
Characteristic Non-Preeclamptic (n = 757) Preeclamptic (n = 34) P Value†
Maternal age (years; mean ± SD) 28.2 ± 6.5 26.3 ± 6.1 0.10
Race: African American (n [%]) 347 (46) 20 (59) 0.14
Weight (lb; mean ± SD) 162.3 ± 45 160.1 ± 50 0.78
Unmarried (n [%]) 372 (49) 17 (50) 0.92
No insurance (n [%]) 402 (53) 23 (68) 0.10
WIC (n [%]) 165 (22) 7 (21) 0.87
Smoking during pregnancy (n [%]) 131 (17) 4 (11.8) 0.40
Nulliparous (n [%]) 297 (39) 16 (47) 0.36
Gestational age (weeks; mean ± SD) at delivery 38.5 ± 2.5 35.5 ± 3.2 <0.0001
Gestational age (weeks; mean ± SD) at blood draw 14.9 ± 4.9 14.6 ± 4.3 0.68
WIC = Special Supplemental Nutrition Program for Women, Infants, and Children.
*
Data based on 791 women at enrollment.
†
χ2 or Student t test.
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Table 2
Oxidative Stress and Periodontal Disease Status Among the Study Population
Oxidative Stress/Periodontal Status Non-Preeclamptic (n = 757) Preeclamptic (n = 34) P Value
8-Isoprostane (pg/ml; median [IQR]) 1,637 (16 to 81,430) 15,834 (448 to 1,000,500) 0.08
8-Isoprostane (pg/ml; mean ± SD) 191,891 ± 393,742 356,261 ± 569,666 0.11
8-Isoprostane ≥75th percentile (n [%]) 185 (24) 13 (38) 0.07
Moderate/severe periodontal disease (n [%]) 108 (14) 6 (18) 0.58
8-Isoprostane ≥75th percentile and periodontal disease (n [%]) 46/50 (92) 4/50 (8) 0.18
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Table 3
Periodontal Disease, Percentile of 8-Isoprostane Concentration, and Risk for Preeclampsia
Periodontal Status/8-Isoprostane Percentile Adjusted OR (95% CI)*
Healthy/mild/<75 1.0 (referent)
Healthy/mild/≥75 1.69 (0.74 to 3.84)
Moderate/severe/<75 0.80 (0.18 to 3.59)
Moderate/severe/≥75 2.08 (0.65 to 6.60)
*
Adjusted for African American race and smoking status.
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